Rationale and study design of the RESERVOIR trial: A randomized trial comparing reservoir‐based polymer‐free amphilimus‐eluting stents versus everolimus‐eluting stents with durable polymer in patients with diabetes mellitus

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 85, Iss. 4, 2015-03 ,pp. : E116-E122

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison of 2‐year outcomes between zotarolimus‐eluting and everolimus‐eluting new‐generation cobalt–chromium alloy stents in real‐world diabetic patients

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 86, Iss. 1, 2015-07 ,pp. : E11-E18

John Wiley & Sons Inc

Access to resources Recommend Favorite

Five‐year clinical follow‐up of a randomized comparison of a polymer‐free sirolimus‐eluting stent versus a polymer‐based paclitaxel‐eluting stent in patients with diabetes mellitus (LIPSIA Yukon trial)

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 83, Iss. 3, 2014-02 ,pp. : 418-424

John Wiley & Sons Inc

Access to resources Recommend Favorite

Risk and timing of clinical events according to diabetic status of patients treated with everolimus‐eluting bioresorbable vascular scaffolds versus everolimus‐eluting stent: 2‐year results from a propensity score matched comparison of ABSORB EXTEND and SPIRIT trials

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 91, Iss. 3, 2018-02 ,pp. : 387-395

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents in patients with coronary artery disease

By Zhang Feng   Dong Lili   Qian Juying   Ge Junbo  

Annals of Medicine, Vol. 43, Iss. 1, 2011-02 ,pp. : 75-79

Informa Healthcare

Access to resources Recommend Favorite